Indication
Pancreatic Adenocarcinoma
47 clinical trials
70 products
21 drugs
Clinical trial
A Multicenter Open-label Phase 1 Trial to Evaluate Safety and Preliminary Efficacy of Endovascularly Applied Vascular Targeted Photodynamic Therapy (VTP) for Patients With Locally Advanced Unresectable Pancreatic Ductal AdenocarcinomaStatus: Not yet recruiting, Estimated PCD: 2025-04-30
Product
PadeliporfinClinical trial
Phase Ib/II Trial of Y101D Combined With Gemcitabine and Albumin Paclitaxel in First-line Treatment of Patients With Advanced Pancreatic CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-30
Product
Y101DClinical trial
An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the PancreasStatus: Active (not recruiting), Estimated PCD: 2022-07-23
Product
5FluorouracilProduct
LeucovorinProduct
Nab-paclitaxelProduct
GemcitabineProduct
Irinotecan LiposomalProduct
OxaliplatinProduct
Ga-OncoFAPClinical trial
A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Patients With Solid TumorsStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 1/2a Study of IMM-6-415 in Participants With Advanced or Metastatic Malignancies Harboring RAS or RAF Oncogenic MutationsStatus: Recruiting, Estimated PCD: 2027-06-01
Product
IMM-6-415Product
MilademetanProduct
AtezolizumabClinical trial
A Phase 1b/2Study of Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss (MANTRA-4)Status: Withdrawn, Estimated PCD: 2023-05-30
Clinical trial
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2024-09-30
Product
Nab PaclitaxelClinical trial
A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients With gBRCA Mutated Metastatic Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum Based ChemotherapyStatus: Completed, Estimated PCD: 2019-01-15
Product
OlaparibProduct
PlaceboClinical trial
A Randomized Pilot/Pharmacodynamic/Genomic Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic CancerStatus: Completed, Estimated PCD: 2015-12-01
Product
ParicalcitolDrug
AbraxaneDrug
GemcitabineClinical trial
A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic CancerStatus: Completed, Estimated PCD: 2013-08-01
Drug
fluorouracilProduct
NelfinavirClinical trial
Phase Ib/II Open-Label, Multicenter, Randomized Study Evaluating the Safety and Efficacy of 'Switch Maintenance' Combination Immunotherapy Using AB154, AB122, and APX005M in Patients With Metastatic Pancreatic CancerStatus: Recruiting, Estimated PCD: 2026-01-31
Product
ZIMBERELIMABProduct
DOMVANALIMABProduct
APX005MProduct
FOLFIRIClinical trial
A Single-arm Multicentre Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Who Have Not Previously Received Therapy for Metastatic Adenocarcinoma of the PancreasStatus: Not yet recruiting, Estimated PCD: 2025-08-28
Drug
mFOLFOX6Product
LLVProduct
5-FUClinical trial
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2022-06-22
Product
CediranibClinical trial
Phase II Study of Neoadjuvant Intraperitoneal Gemcitabine and Intravenous Gemcitabine With Radiotherapy Followed by Surgery and Adjuvant Intraperitoneal Gemcitabine, Intravenous Gemcitabine, and Fluorouracil in Patients With Advanced Adenocarcinoma of the PancreasStatus: Completed
Product
gemcitabineClinical trial
Phase I/II Study of Neoadjuvant mFOLFIRINOX in Combination With Peri-operative Oral Hydroxychloroquine (FHQ) in Subjects With Resectable Adenocarcinoma of the Pancreas.Status: Recruiting, Estimated PCD: 2025-06-01
Product
HydroxychloroquineClinical trial
Phase II Trial of In Situ Tumor Vaccination Using Durvalumab and "Booster" Radiation Therapy in Patients With Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Through First-line ChemotherapyStatus: Terminated, Estimated PCD: 2020-07-09
Drug
AN0025Clinical trial
A Phase IIa (Pilot) Study of Neoadjuvant Chemotherapy With Folinic Acid, 5-FU, Irinotecan and Oxaliplatin (FOLFIRINOX) With Digoxin in Patients With Resectable Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-02-01
Product
DigoxinProduct
Calcium LeucovorinDrug
mFOLFOXIRIClinical trial
Phase II Trial of Paricalcitol and Hydroxychloroquine (PH) Combination With Gemcitabine and Nab-Paclitaxel in Advanced or Metastatic Pancreatic CancerStatus: Active (not recruiting), Estimated PCD: 2024-08-14
Clinical trial
Nano-SMART: An Adaptive Phase I-II Trial of AGuIX Gadolinium-based Nanoparticles With Stereotactic Magnetic Resonance-guided Adaptive Radiation Therapy for Centrally Located Lung Tumors and Locally Advanced Unresectable Pancreatic Ductal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2026-04-10
Product
AGuIXClinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIMEStatus: Terminated, Estimated PCD: 2020-12-10
Product
CopanlisibClinical trial
Quantitative In Vivo 68Ga-Fibroblast-Activation-Protein-Inhibitors (FAPI)-46 PET Imaging of Cancer-Associated Fibroblasts (CAFs) in Pancreatic Ductal Adenocarcinoma (PDA)Status: Recruiting, Estimated PCD: 2027-06-30
Product
Gallium Ga 68 FAPi-46Clinical trial
Phase 2 Single Arm Trial Testing the ZN-c3 WEE1 Inhibitor in Combination With Gemcitabine in Second-Line Advanced Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2026-06-01
Product
ZentalisProduct
AbemaciclibProduct
AbirateroneProduct
AfatinibDrug
AtezolizumabProduct
BicalutamideProduct
BortezomibClinical trial
Phase 1 Dose Escalation Trial of ZM008, an Anti-LLT1 Antibody, as Single Agent Followed by Combination With Pembrolizumab in Patients With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-01
Product
ZM008Clinical trial
Intraoperative Near-infrared Fluorescence Imaging in Pancreatic- and Extrahepatic Bile Duct Tumors Using cRGD-ZW800-1 and Dedicated Imaging Systems: A Phase II Feasibility Testing, Dose-ranging and Optimal Dose-(Interval) Selection TrialStatus: Completed, Estimated PCD: 2024-05-23
Product
CRGD-ZW800-1Product
CabazitaxelProduct
DabrafenibProduct
DarolutamideProduct
DacomitinibProduct
CabozantinibDrug
UTD1Drug
CelecoxibProduct
CobimetinibProduct
DasatinibDrug
R-CHOPClinical trial
Weight Loss in Patients With Advanced Stage Pancreatic Cancer: Role of Serotonin and Effects of Telotristat EthylStatus: Active (not recruiting), Estimated PCD: 2023-10-26
Product
Telotristat EthylProduct
EnasidenibDrug
EntrectinibProduct
EnzalutamideClinical trial
A Phase IIb Pilot Study to Assess the Efficacy, Safety, and Pharmacodynamics Effects of Pembrolizumab and BL-8040 in Patients With Metastatic Pancreatic CancerStatus: Completed, Estimated PCD: 2023-10-06
Product
BL-8040Clinical trial
Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic CancerStatus: Recruiting, Estimated PCD: 2027-07-01
Product
IrinotecanDrug
5-FUClinical trial
Sequential Use of Nab-paclitaxel Plus Gemcitabine and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer: A Randomized Control StudyStatus: Recruiting, Estimated PCD: 2025-10-20
Product
AG RegimenProduct
mFolfirinoxClinical trial
Phase 1 Trial of Gemcitabine Combined With the Elimusertib (BAY 1895344) ATR Inhibitor With Expansion Cohorts in Advanced Pancreatic and Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-01
Product
ElimusertibClinical trial
Sequential Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2028-07-01
Product
Nab paclitaxelClinical trial
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin+ Hydroxychlororoquine as Preoperative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the PancreasStatus: Active (not recruiting), Estimated PCD: 2023-05-23
Product
PaclitaxelDrug
CisplatinClinical trial
A Phase I Dose-Escalation Study of CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2026-08-01
Product
CPI-613Clinical trial
BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients With Advanced Solid Tumors, Phase I Studies With Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)Status: Active (not recruiting), Estimated PCD: 2025-02-15
Product
TopotecanClinical trial
Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic AdenocarcinomaStatus: Completed, Estimated PCD: 2022-09-30
Drug
T-VECClinical trial
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-12-31
Drug
DefactinibClinical trial
A Phase 1/Randomized Phase 2 Study of M3814 (Peposertib) in Combination With Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-08-01
Product
PeposertibClinical trial
A Phase II Trial of Pre-operative Chemotherapy (With Gemcitabine and Nab- Paclitaxel) and Stereotactic Body Radiotherapy Followed by Surgery and Chemotherapy in Patients With Resectable Pancreatic AdenocarcinomaStatus: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
Photodynamic Priming to Facilitate Immunologic Activity of Anti-PD1 in Patients With Pancreatic CancerStatus: Not yet recruiting, Estimated PCD: 2029-07-04
Drug
FOLFOXIRIProduct
Photodynamic TherapyProduct
VerteporfinClinical trial
18F-FAPI PET/CT and 18F-FDG PET/CT in Patients With Pancreatic Adenocarcinoma : A Prospective, Single-Center, Comparative StudyStatus: Completed, Estimated PCD: 2023-02-28
Product
18F-FAPIDrug
FDGClinical trial
A Phase II Open-Label Study of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma (EPIC)Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Combining Epigenetic And Immune Therapy to Beat Cancer. CAIRE StudyStatus: Recruiting, Estimated PCD: 2023-07-01
Product
TazemetostatClinical trial
CATRIPCA - A Phase I Study of PD1 Monoclonal Antibody (Pembrolizumab) In Combination With a IAP Antagonist (Debio 1143) In (Exocrine) Pancreatic And Colorectal Non MSI-high Advanced/Metastatic Adenocarcinoma.Status: Completed, Estimated PCD: 2022-05-30
Product
DEBIO1143Clinical trial
Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic CancerStatus: Completed, Estimated PCD: 2021-09-14
Product
Ascorbic AcidClinical trial
An Open-Label, Phase II Trial to Assess Efficacy and Safety of Onvansertib in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Previously Untreated, Locally-Advanced or Unresectable Pancreatic AdenocarcinomaStatus: Not yet recruiting, Estimated PCD: 2026-05-04
Product
OnvansertibClinical trial
A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-07-01
Drug
MotixafortideProduct
CemiplimabClinical trial
SHAPER: A Phase 1 Study of Losartan and Hypofractionated Radiation Therapy After Induction Chemotherapy for Borderline Resectable or Locally Advanced Pancreatic CancerStatus: Recruiting, Estimated PCD: 2025-08-08
Drug
LosartanClinical trial
A Phase 1b Study of Gemcitabine and Leflunomide in Patients With Unresectable Pancreatic CancerStatus: Recruiting, Estimated PCD: 2026-11-13
Product
CholestyramineProduct
Leflunomide